RT Journal Article
SR Electronic
T1 Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.08.20224790
DO 10.1101/2020.11.08.20224790
A1 Jonathon W. Senefeld
A1 Stephen A. Klassen
A1 Shane K. Ford
A1 Chad C. Wiggins
A1 Bruce C. Bostrom
A1 Michael A. Thompson
A1 Sarah E. Baker
A1 Wayne T. Nicholson
A1 Patrick W. Johnson
A1 Rickey E. Carter
A1 Jeffrey P. Henderson
A1 William R. Hartman
A1 Liise-anne Pirofski
A1 R. Scott Wright
A1 DeLisa Fairweather
A1 Katelyn A. Bruno
A1 Nigel S. Paneth
A1 Arturo Casadevall
A1 Michael J. Joyner
YR 2020
UL http://medrxiv.org/content/early/2020/11/10/2020.11.08.20224790.abstract
AB In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ), grant F32HL154320 (to JWS), and grant RO1 HL059842 (to AC); Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK); National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21 AI154927 (to DF), and grant R01 AI152078 9 (to AC); and National Institute on Aging (NIA) U54AG044170 (to SEB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures accessed public information and did not require ethical review as determined by the Mayo Clinic Institutional Review Board in accordance with the Code of Federal Regulations, 45 CFR 46.102, and the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese data are publicly available in the primary literature in which these data were abstracted.